# Efficacy of Upadacitinib Re-induction Therapy in Patients With Ulcerative Colitis Who Lost Response to 30 mg Maintenance Dose

> **NCT07700446** · PHASE4 · NOT_YET_RECRUITING · sponsor: **Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives** · enrollment: 100 (estimated)

## Conditions studied

- Ulcerative Colitis (UC)

## Interventions

- **DRUG:** Upadacitinib

## Key facts

- **NCT ID:** NCT07700446
- **Lead sponsor:** Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-11-15
- **Primary completion:** 2029-11
- **Final completion:** 2030-04
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2026-07-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07700446

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07700446, "Efficacy of Upadacitinib Re-induction Therapy in Patients With Ulcerative Colitis Who Lost Response to 30 mg Maintenance Dose". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07700446. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*